NCT00849134View on ClinicalTrials.gov

First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 17, 2008

Primary Completion Date

April 6, 2009

Study Completion Date

April 6, 2009

Conditions
Pain, Inflammatory
Interventions
DRUG

GSK1482160 or placebo

GSK1482160 is a P2X7 receptor antagonist

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY